Johnson & Johnson (NYSE: JNJ) reported better-than-expected third-quarter financial results on Tuesday. The drugmaker raised its full-year guidance, saying it now expects per-share earnings of between $7.95 and $8.05, up from its previous forecast in July of between $7.75 and $7.95.
"Our...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.